CheckMate 649: 1L nivo + chemotherapy improves OS

(6:54)

CheckMate 649: nivolumab and chemotherapy or ipilimumab in GC/GEJC/EAC

(1:44)

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC

(6:31)

CheckMate 649 3-Year Follow-up: Nivolumab Plus Chemotherapy for Gastric and Esophageal Cancers

(6:23)

Checkmate 649 | Out now on Plenary Session Podcast feed

(1:30)

Rationale and study design of CheckMate-649 biomarker analysis

(4:21)

3-year follow-up of CheckMate 649: nivolumab + chemotherapy in GC/GEJC/EAC

(1:22)

Biomarker analyses of the CheckMate 649 trial in GC/GEJC/EAC

(4:43)

Future directions of research following the CheckMate-649 trial

(2:9)

Jaffer Ajani, MD, considers results from the CheckMate 649 study presented at ESMO 2020

(2:28)

Nivolumab chemotherapy combination treatment: CheckMate649 and ATTRACTION-4

(4:47)

Expert Video Report on immunotherapy in gastro oesophageal cancer from 2021 ASCO Annual Meeting

(11:12)

NIVO + chemo vs chemo as 1L treatment for advanced GC/GEJC/EAC: 4 year yr follow-up of CheckMate 649

(2:26)

Advances in adjuvant and 1L immune checkpoint blockade for gastric and esophageal cancer

(4:29)

#ESMO21 Expert Video Report on immunotherapy in gastro-oesophageal cancer

(7:25)

Part 2 - Nivolumab with chemotherapy in advanced previously untreated Gastric - Dr. Anant Ramaswamy

(7:12)

29-month follow-up from CheckMate 648: nivolumab combination therapy in ESCC

(1:19)

Adding Immunotherapy to First-Line Chemotherapy for Gastric Cancer: Data and Implications

(14:12)

CheckMate 649, un approfondimento sul follow-up a 4 anni

(6:17)

What role will zolbetuximab play in treating gastric cancer?

(1:44)